PRTA Prothena: Enterprise Value to EBITDA Ratio
Prothena Corporation (PRTA) is developing cutting-edge methods to combat neuronal degradation, competing with industry leaders for technological primacy. The confirmed price history on the chart shows that the EV/EBITDA dynamics are 0.00, while global conflicts and trade restrictions hinder international testing and raw material supplies. The business's success relies on research results, remaining independent of economic cycles, which only affect investment demand.
Prothena Corporation plc - analytical breakdowns and key metrics (PRTA)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
Debt to Equity Prothena Corporation|PRTA - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Prothena Corporation PLC|PRTA - Company Aggregate Debts|Debt to Book Value Prothena Biosciences|PRTA - Company Long-Term Loans and Borrowings|Company Short-Term Debts Prothena|Quick Liquidity prothena.com
- financial results and valuation multiples details:
PRTA - Company Net Income|Expected Profit Prothena Corporation|PRTA - Company Value to Net Income|Future Price to Earnings Prothena Corporation|PRTA - Market Cap to Earnings and Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Prothena Biosciences|PRTA - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Prothena|PRTA - Earnings per share for the trailing year|Quarterly EPS earnings growth prothena.com|PRTA - Earnings growth in current year|Expected earnings per share growth for next year Prothena Corporation
Fundamental company analysis:Prothena Biosciences (PRTA)
Fundamental asset screening begins by determining the fair value of a business relative to its debt load. The EV/EBITDA valuation multiple, used for capital-intensive businesses, compares the total enterprise value of a company with its operating profit before depreciation and taxes. Analyzing the trend on this chart allows for the identification of points of extreme asset undervaluation. For Prothena Corporation (PRTA), this indicator is critical, as inelastic demand for unique protein therapies provides significant pricing power.
Key competitors
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biogen Corp BIIB|Neurocrine Corp (NBIX) - Company Value to EBITDA|RGC: Enterprise Value to EBITDA Ratio|axsome.com - Enterprise Value to Operating Income Before Depreciation Ratio|ACAD: EV/EBITDA Multiple|Xenon Pharmaceuticals Inc. - Business Value to Operating Income Before Depreciation|VKTX (Viking Pharma) - EV/EBITDA Multiple|Company Value to EBITDA Supernus Corp SUPN|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Catalyst Pharmaceuticals (CPRX)|denalitherapeutics.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple HRMY (Harmony Biosciences Holdings, Inc.)|EV/EBITDA Multiple Biohaven Ltd BHVN|AMLX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation TRVI (Trevi Corp)|PRAX: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio anavex.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CeriBell|Company Value to EBITDA Alector Therapeutics ALEC|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Annexon Inc. (ANNX)|OMER (omeros.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Neurogene Inc. NGNE|ACIU (acimmune.com) - Company Value to Operating Income Before Depreciation Ratio|VYGR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Neumora|Scilex Holding Co. (SCLX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Tevogen Bio Inc. - Business Value to Operating Income Before Depreciation|ACOG (Alpha Cognition Inc) - EV/EBITDA Multiple|EV/EBITDA Multiple cogrx.com|Enterprise Value to EBITDA Ratio IKT (Inhibikase Therapeutics, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio SAVA|EV/EBITDA Multiple ASRT (Assertio)|Total Company Value to Operating Income Before Depreciation Ratio Coya Therapeutics Inc (COYA)|VTGN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Ovid Therapeutics Inc.|Acumen Pharmaceuticals, Inc. (ABOS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation CRVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alterity Therapeutics Ltd.|Clene Nanomedicine - Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PepGen Inc. (PEPG)|JUNS (jupiterneurosciences.com) - Business Value to Operating Income Before Depreciation|Relmada Therapeutics, Inc. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio ANVS (Annovis Bio Inc)|Grace Tx - EV/EBITDA Multiple|AIFF - EV/EBITDA Multiple|anewmeds.com (KLTO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation NRSN|RVPH (Reviva Pharmaceuticals Holdings, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA MetaVia, Inc. MTVA|Enterprise Value to EBITDA Ratio NRXS (NeurAxis, Inc)|EV/EBITDA Multiple heliusmedical.com (HSDT)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Passage Bio PASG|Business Value to Operating Income Before Depreciation NEUP|NERV - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Athira Pharma Inc|Addex Therapeutics, Ltd. (ADXN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio ALZN (Alzamend Neuro)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cyclerion Therapeutics Inc.|PTIX: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pasithea Therapeutics (KTTA)|CRGT - Company Value to EBITDA|Avenue Therapeutics, Inc - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio BCLI (BrainStorm Cell Therapeutics Inc.)|Cara Therapeutics, Inc. - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation CHRO (chromocell.com)|ELYM: EV/EBITDA Multiple|Company Value to EBITDA Intra-Cellular Therapies, Inc. (ITCI)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Longboard Pharma|Enterprise Value to Operating Income Before Depreciation MRNS (Marinus Pharma)|EV/EBITDA Multiple NKGN|EV/EBITDA Multiple neurobopharma.com (NRBO)|Sage Therapeutics - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation SNPX|Trevena, Inc - EV/EBITDA Multiple|Vigil Neuroscience (VIGL) - Enterprise Value to EBITDA Ratio|Anew Medical, Inc. (WENA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA cerevel.com (CERE)
